Vanda Pharmaceuticals annual debt-to-ebitda ratio
2018
2019
2020
2021
2022
Vanda Pharmaceuticals Debt-to-EBITDA Ratio Growth & History (VNDA)
Vanda Pharmaceuticals's debt-to-ebitda ratio was 1.23 for fiscal 2022.
View full Vanda Pharmaceuticals company overviewVanda Pharmaceuticals annual debt-to-ebitda ratio history
| Fiscal year | Period ended | Debt-to-EBITDA ratio | Change | Growth |
|---|---|---|---|---|
| 2022 | 2022-12-31 | 1.23 | 0.95 | +347.45% |
| 2021 | 2021-12-31 | 0.27 | −0.18 | −39.24% |
| 2020 | 2020-12-31 | 0.45 | −0.12 | −20.40% |
| 2019 | 2019-12-31 | 0.57 | 0.57 | — |
| 2018 | 2018-12-31 | 0.00 | — | — |
Vanda Pharmaceuticals quarterly debt-to-ebitda ratio
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
| Fiscal quarter | Period ended | Debt-to-EBITDA ratio | Change | YoY change |
|---|---|---|---|---|
| Q3 2023 | 2023-09-30 | 4.31 | 3.31 | +331.10% |
| Q2 2023 | 2023-06-30 | 0.84 | 0.20 | +31.34% |
| Q1 2023 | 2023-03-31 | 0.57 | 0.13 | +29.50% |
| Q4 2022 | 2022-12-31 | 1.23 | 0.95 | +347.45% |
| Q3 2022 | 2022-09-30 | 1.00 | 0.73 | +266.89% |
| Q2 2022 | 2022-06-30 | 0.64 | 0.34 | +116.98% |
| Q1 2022 | 2022-03-31 | 0.44 | 0.12 | +35.65% |
| Q4 2021 | 2021-12-31 | 0.27 | −0.18 | −39.24% |
| Q3 2021 | 2021-09-30 | 0.27 | −0.29 | −51.89% |
| Q2 2021 | 2021-06-30 | 0.29 | −0.22 | −42.95% |
| Q1 2021 | 2021-03-31 | 0.33 | −0.19 | −36.52% |
| Q4 2020 | 2020-12-31 | 0.45 | −0.12 | −20.40% |
| Q3 2020 | 2020-09-30 | 0.57 | 0.08 | +16.21% |
| Q2 2020 | 2020-06-30 | 0.52 | −0.07 | −11.61% |
| Q1 2020 | 2020-03-31 | 0.51 | −0.26 | −33.33% |
| Q4 2019 | 2019-12-31 | 0.57 | 0.57 | — |
| Q3 2019 | 2019-09-30 | 0.49 | — | — |
| Q2 2019 | 2019-06-30 | 0.58 | — | — |
| Q1 2019 | 2019-03-31 | 0.77 | — | — |
| Q4 2018 | 2018-12-31 | 0.00 | — | — |
Vanda Pharmaceuticals debt-to-ebitda ratio trends
Between the periods ended 2018-12-31 and 2022-12-31, Vanda Pharmaceuticals's debt-to-ebitda ratio increased from 0.00 to 1.23, a change of 1.23. The latest reported quarter, Q3 2023, shows 4.31.
About the metric
What the debt-to-EBITDA ratio means
Debt-to-EBITDA compares interest-bearing debt with operating earnings before interest, taxes, depreciation, and amortization. It is commonly used to assess leverage, but it is generally unsuitable for banks and other financial companies.
Calculation and source
How debt-to-EBITDA is calculated
TickerStat divides period-end total debt by annual EBITDA. Quarterly observations use trailing-12-month EBITDA. Periods with zero or negative EBITDA are excluded because the leverage multiple would not be meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vanda Pharmaceuticals source filings ↗